Initial Presentations Predict Mortality in Pulmonary Tuberculosis Patients - A Prospective Observational Study by Feng, Jia-Yih et al.
Initial Presentations Predict Mortality in Pulmonary
Tuberculosis Patients - A Prospective Observational
Study
Jia-Yih Feng
1,2, Wei-Juin Su
1,3*, Yu-Chi Chiu
1, Shiang-Fen Huang
1, Yung-Yang Lin
4,5, Ruay-Ming Huang
6,
Ching-Hsiung Lin
7, Jhi-Jhu Hwang
8, Jen-Jyh Lee
9, Ming-Chih Yu
10, Kwok-Woon Yu
11, Yu-Chin Lee
1,3
1Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China, 2Institute of Clinical Medicine, National Yang-Ming University,
Taipei, Taiwan, Republic of China, 3School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China, 4Institute of Clinical Medicine and Institute of
Brain Science, National Yang-Ming University, Taipei, Taiwan, Republic of China, 5Laboratory of Neurophysiology and Department of Neurology, Taipei Veterans General
Hospital, Taipei, Taiwan, Republic of China, 6Hua-Lien Hospital, Department of Health, Executive Yuan, Hua-Lien County, Taiwan, Republic of China, 7Division of Chest
Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan, Republic of China, 8Division of Pulmonary and Critical Care, Department of
Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan, Republic of China, 9Department of Internal Medicine, Buddhist Tzu Chi
General Hospital, Tzu Chi University, Hualien, Taiwan, Republic of China, 10Department of Internal Medicine, Wan Fang Hospital, Taipei, Taiwan, Republic of China,
11Division of Clinical Microbiology, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
Abstract
Background: Despite effective anti-TB treatments, tuberculosis remains a serious threat to public health and is associated
with high mortality. Old age and multiple co-morbidities are known risk factors for death. The association of clinical
presentations with mortality in pulmonary tuberculosis patients remains an issue of controversy.
Methods: This prospective observational study enrolled newly diagnosed, culture-proven pulmonary tuberculosis patients
from five medical centers and one regional hospital, which were referral hospitals of TB patients. Radiographic findings and
clinical symptoms were determined at the time of diagnosis. Patients who died for any reason during the course of anti-TB
treatment were defined as mortality cases and death that occurred within 30 days of initiating treatment was defined as
early mortality. Clinical factors associated with overall mortality and early mortality were investigated.
Results: A total of 992 patients were enrolled and 195 (19.7%) died. Nearly one-third (62/195, 31.8%) of the deaths occurred
before or within 30 days of treatment initiation. Older age (RR=1.04, 95%CI: 1.03–1.05), malignancy (RR=2.42, 95%CI: 1.77–
3.31), renal insufficiency (RR=1.77, 95%CI: 1.12–2.80), presence of chronic cough (RR=0.63, 95%CI: 0.47–0.84), fever
(RR=1.45, 95%CI: 1.09–1.94), and anorexia (RR=1.49, 95%CI: 1.07–2.06) were independently associated with overall
mortality. Kaplan-Meier survival analysis demonstrated significantly higher mortality in patients present with fever
(p,0.001), anorexia (p=0.005), and without chronic cough (p,0.001). Among patients of mortality, those with respiratory
symptoms of chronic cough (RR=0.56, 95%CI: 0.33–0.98) and dyspnea (HR=0.51, 95%CI: 0.27–0.98) were less likely to
experience early mortality. The radiological features were comparable between survivors and non-survivors.
Conclusions: In addition to demographic characteristics, clinical presentations including the presence of fever, anorexia, and
the absence of chronic cough, were also independent predictors for on-treatment mortality in pulmonary tuberculosis
patients.
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Introduction
Pulmonary tuberculosis (PTB) is an infectious disease with
airborne transmission that is associated with high morbidity and
mortality worldwide. Despite the advances in anti-tuberculosis
(anti-TB) medications and the use of a Direct Observation
Therapy/Short Course (DOTS) strategy, the tuberculosis mortal-
ity rates remain high in many areas, including Taiwan [1–4].
Globally, it has been estimated that tuberculosis causes 1.7 million
deaths each year, or about three deaths each minute [1].
Investigating the clinical factors associated with mortality is of
paramount importance for the management of PTB patients. The
early identification of high risk patients can enable clinicians to
provide more aggressive and intensive treatments. Age and
underlying co-morbidities have been frequently reported as
independent predictors of mortality in previous studies [4–6]. By
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the bacilli loads in sputum have been less frequently mentioned as
independent risk factors [7]. Studies that evaluated the impacts of
drug susceptibility profiles on mortality also reported controversial
results [3,6]. Most of these predictors of mortality were non-
modifiable factors.
Interestingly, the predictive values of the initial presentations of
PTB on mortality have rarely been evaluated and have shown
inconsistent results [3,8–10]. Although the symptoms/signs of
PTB are usually non-specific, typical presentations, such as
chronic cough, afternoon fever, and unexplained body weight
loss, remain important hints to remind clinical physicians to
consider a diagnosis of tuberculosis. In addition, the clinical
presentations reflect the interactions between pathogens and host
immune responses. The major purpose of the present study was to
evaluate the associations of initial presentations for predicting the
mortality of PTB patients. The mortality profiles of PTB patients
and other clinical predictors of mortality, including bacilli
genotyping, were also investigated.
Materials and Methods
Ethics
This study was approved by the Institutional Review Board of
Taipei Veterans General Hospital; Chest Hospital, DOH,
Institutional Review Board; Changhua Christian Hospital Institu-
tional Review Board; Kaohsiung Medical University Chung-Ho
Memorial Hospital Institutional Review Board; Taipei Medical
University- Wang Fang Medical Center Institutional Review
Board; Buddhist Tzu Chi General Hospital and Tzu Chi
University, Hualien, Research Ethics Committee; and Chest
Hospital, Department of Health, Executive Yuan, Research Ethics
Committee. Written informed consent was obtained from each
patient or their authorized representative(s) before enrollment.
Patients and setting
This prospective observational study was conducted at six
hospitals in Taiwan: five referral medical centers and 1 regional
hospital specializing in pulmonary diseases. Newly diagnosed,
culture-proven tuberculosis patients from January 2007 to June
2009 were eligible for enrollment. Patients without pulmonary
involvement and those who were younger than 18 years of age
were excluded. Demographic profiles (age, gender, co-morbidities)
and clinical characteristics (history of previous anti-TB treatments,
and smoking habits) were obtained from the patients by
enrollment interview. The presenting symptoms/signs were
determined according to the subjective statements of the patients
and/or their caregivers in critical ill patients. In patients with
altered mental status, the presence of dyspnea was determined
when the respiratory rate excessed 25/minute. Drug susceptibility
profiles were collected from medical records.
Initial presentations were divided into pulmonary symptoms/
signs (chronic cough lasting longer than 3 weeks, hemoptysis, and
dyspnea) and constitutional symptoms/signs (body weight loss,
fever, malaise, and anorexia). Chest radiographs were reviewed by
the doctor in-charge at each hospital. Patients were categorized as
having cavitation, lobar/segmental consolidation, or bilateral
disease if these were present on chest radiographs at the time of
diagnosis.
Treatment of pulmonary tuberculosis and follow-up
All of the patients were treated with standard anti-TB
treatments that included isoniazid, rifampicin, ethambutol, and
pyrazinamide in the initial phase. The regimen was modified when
drug susceptibility results were available or when significant
adverse effects occurred. All of the patients were followed until
death or upon completion of anti-TB treatment. The treatment
outcome was determined according to the records in the Centers
for Disease Control (CDC) registration database, Taiwan. Patients
who died for any reason before or during the course of anti-TB
treatment were defined as mortality cases and mortality that
occurred within 30 days of initiating PTB treatment was defined as
early mortality [11] Defaulted cases and patients who were
transferred out were excluded from analysis.
Mycobacteriology and genotyping
Sputum AFB smears and cultures were performed in each
hospital using standard methods. Sputum smears were examined
through Ziehl-Neelsen staining. The isolation of MTB in sputum
cultures was performed in liquid medium (BACTEC) and/or
Lowenstein-Jensen solid medium. Drug susceptibility testing was
performed using the proportion method with Middlebrook 7H11
media. Genomic DNA was extracted from cultures as described
previously [12]. All clinical isolates were genotyped using a
commercial spoligotyping kit (Isogen Bioscience B.V., Maarssen,
Netherlands). The ‘‘Beijing strain’’ was defined as a deletion from
spacer 1 to spacer 34 in the direct repeat region and the presence
of (at least 3) spacers in 35–43.
Statistical analysis
The cumulative incidence of mortality was estimated by
Kaplan-Meier analysis. The statistical significances and risk ratios
of overall and early (deaths within 30 days) mortality by clinical
characteristics were analyzed using unadjusted and adjusted
Poisson regression analysis with a stepwise selection procedure.
The proportional-hazards assumption was tested on the basis of
Schoenfeld residuals after a fitted Cox regression model. For time
varying covariates, i.e. the hazard ratios for dying varied with
follow-up time, averaged hazard ratios were reported. A p value of
, 0.1 in unadjusted model was required for a variable to be
entered into the adjusted model. Variables were included in the
final model for p,0.05 and were excluded if p,0.1. Survival time
was estimated by the Kaplan-Meier method and a log-rank test
was used to evaluate factors associated with death. The patients of
defaults and transferred out were censored in the Kaplan-Meier
survival analysis. A p value of , 0.05 (two-tailed) was considered
statistically significant for all tests. Statistical analysis used SPSS
version 14.0 (SPSS Inc., Chicago, IL, USA) and STATA 11.0
(Stata corporation, College Station, Texas, USA).
Results
PTB Patient Mortality
The study profile showing the number of cases and reasons for
exclusion is shown in Figure 1. Ultimately, 992 patients with newly
diagnosed, culture-proved pulmonary tuberculosis were included
for analysis.
Overall, 992 patients were followed up for 646.8 person-year.
Of these patients, 62 (6.3%) died within 30 days, 185 (18.6%) died
within one year, and 195 (19.7%) died before completing
treatment. The 30-day and one-year cumulative mortality was
6.25% (95% CI:4.91%–7.94%) and 22.55% (95% CI: 18.95%–
26.71%), respectively. The survival times for PTB patients in the
first 60 days and within one year are shown in Figure 2. The first
40 days had the largest numbers of mortality cases, and these
numbers gradually declined thereafter.
All the 21 pre-treatment mortality cases were diagnosed by positive
sputum culture results and enrolled before mortality. However, the
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the patients died before initiation of treatment. The delay in anti-TB
treatment was mostly due to concomitant hepatic and renal
dysfunction, inability to take oral medications, or by clinical judgment
of the in charge physicians. The intervals from diagnosis to mortality
ranged from 13 days to 1 day in these patients.
Clinical Presentations of Survivors and Non-survivors
The demographic characteristics and clinical presentations of
the study population are shown in Table 1. Their mean age was
64.6 (619.2) years and they were predominantly males (77.6%).
There were 13 (1.3%) HIV-positive patients. Compared with
survivors, non-surviving patients were more likely to be male
(85.6% vs. 75.7%, p=0.003), older in age (76.2612.6 vs.
61.5619.5, p,0.001), have some malignancy (31.3% vs. 8.9%,
p,0.001), have renal insufficiency (11.8% vs. 3.3%, p,0.001),
and were post-gastrectomy (7.2% vs. 2.1%, p,0.001). The
proportions of HIV-positive patients were comparable between
survivors and non-survivors, and there were no differences in first-
line anti-TB drug resistance rates. The proportions of Beijing
strain infections were similar between the two groups.
Regarding radiological features, the non-survivors were less
likely to have cavity formations (11.3% vs. 20.6%, p=0.003), and
were more likely to have lobar/segmental consolidations (87.2%
vs. 79.9%, p=0.02) and bilateral involvements (49.7% vs. 39.6%,
p=0.01). Regarding clinical symptoms/signs, the non-survivors
were less likely to present with chronic cough of . 3 weeks (42.6%
vs. 62.5%, p,0.001), and were more likely to present with
dyspnea (30.3% vs. 22.5%, p=0.022), fever (42.6% vs. 27.4%,
p,0.001), malaise (21% vs. 13.3%, p=0.006), and anorexia
(25.6% vs. 16.2%, p=0.002). Multivariate Poisson regression
analysis identified age, malignancy, renal insufficiency, chronic
cough, fever, and anorexia as independent predictors associated
with overall mortality.
Independent risk factors associated with overall mortality from a
multivariate Cox proportional hazards model are summarized in
Table 2. Older Age (HR=1.05, 95% CI: 1.04–1.06), malignancy
(HR=2.85, 95% CI: 2.08–3.91), renal insufficiency (HR=2.27,
95% CI: 1.43–3.59), absence of chronic cough . 3 weeks
(HR=0.54, 95% CI: 0.40–0.72), presence of fever (HR=1.72,
95% CI: 1.29–2.30), and anorexia (HR=1.49, 95% CI: 1.07–
2.07) were independent predictors of mortality.
Figure 1. Study profile demonstrating the number of cases and reasons for exclusion.
doi:10.1371/journal.pone.0023715.g001
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absence of clinical symptoms/signs are shown in Figure 3. Patients
who presented with fever, anorexia, and absence of chronic cough
of . 3 weeks had higher mortalities (p,0.001 for fever, p=0.005
for anorexia, and p,0.001 for chronic cough). An absolute
difference in survival between patients with and without chronic
cough was evident after the initiation of anti-TB treatment.
The characteristics of patients with early mortality
The demographic characteristics of patients with early (within
30 days) and late (after 30 days) mortality are shown in Table 3. As
compared with late mortality, patients with early mortality are less
likely to be sputum smear positive (RR: 0.63, 95% CI: 0.41–0.97),
to present with chronic cough . 3 weeks (RR: 0.51, 95% CI:
0.32–0.82) and dyspnea (RR: 0.50, 95% CI: 0.28–0.88). Other
clinical factors, including age, gender, underlying comorbidities,
drug susceptibility profiles, and radiological presentations were
comparable between patients with early or late mortality.
Multivariate Poisson regression analysis identified that the initial
presentations of chronic cough . 3 weeks and dyspnea were
independently associated with a lower probability of early
mortality within 30 days.
Discussion
Despite effective first line anti-TB drugs, pulmonary tubercu-
losis remains a disease with a high mortality rate. The mortality
rates for pulmonary tuberculosis reported in previous studies
Figure 2. Survival time of pulmonary tuberculosis patients after initiation of anti-TB treatment. (A) within one year. (B) within 60 days. *
Number of cases died before initiation of anti-TB treatment.
doi:10.1371/journal.pone.0023715.g002
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morbidities, disease severity, and HIV-infection status of the
included patients [2,6,13,14]. In the present study, 19.7% of the
patients died before completing the treatment, which was
relatively higher as compared with previous reports in non-HIV
endemic areas. The higher mortality rate among the patients we
enrolled was probably due to older age and more underlying co-
morbidities, as the study was performed in referral medical
centers. In line with previous reports [3,15], a higher proportion of
TB patients died in the early phase of commencing treatment.
Nearly one-third of the deaths occurred within 30 days, and more
than half of the deaths occurred within 60 days after initiating anti-
TB treatment. Our observations highlight the importance of
identifying predictors that are associated with mortality in the start
of anti-TB treatment.
The risk factors associated with mortality have been extensively
evaluated before. Age, co-morbidities of malignancy, renal disease,
and respiratory disorders, HIV infection, and malnutrition are all
well-established clinical predictors of mortality in tuberculosis
patients [4–6,8,14,16]. For HIV-infected patients, CD4 T cell
counts and HIV viral loads have been identified as significant
factors of mortality in tuberculosis [2,17]. In addition, low
Table 1. Demographic characteristics and clinical presentations of pulmonary tuberculosis patients with or without on-treatment
mortality.
a
All patients, n=992 Survival status P value
Survivors, n=797 Non-survivors, n=195
Mean age (SD) 64.6 (19.2) 61.5 (19.5) 76.2 (12.6) ,0.001
Male gender 770 (77.6%) 603 (75.7%) 167 (85.6%) 0.003
Previous TB history 94 (9.5%) 76 (9.5%) 18 (9.2%) 0.90
Smoking habit 297 (29.9%) 248 (31.1%) 49 (25.1%) 0.10
Initial sputum smear positive 484 (48.8%) 393 (49.3%) 91 (46.7%) 0.51
Concomitant extrapulmonary TB 38 (3.8%) 30 (3.8%) 8 (4.1%) 0.83
Comorbid diseases
Diabetes 223 (22.5%) 175 (22.0%) 48 (24.6%) 0.43
COPD 75 (7.6%) 55 (6.9%) 20 (10.3%) 0.11
Malignancy 132 (13.3%) 71 (8.9%) 61 (31.3%) ,0.001
Renal insufficiency 49 (4.9%) 26 (3.3%) 23 (11.8%) ,0.001
Liver cirrhosis 34 (3.4%) 25 (3.1%) 9 (4.6%) 0.31
HIV positive
b 13 (1.3%) 12 (1.5%) 1 (0.5%) 0.28
Post gastrectomy 31 (3.1%) 17 (2.1%) 14 (7.2%) ,0.001
Drug susceptibility test
Isoniazid resistance 121 (12.2%) 98 (12.3%) 23 (11.8%) 0.85
Rifampicin resistance 65 (6.6%) 54 (6.8%) 11 (5.6%) 0.57
Ethambutol resistance 73 (7.4%) 59 (7.4%) 14 (7.2%) 0.92
Streptomycin resistance 111 (11.2%) 93 (11.7%) 18 (9.2%) 0.33
MDR 59 (5.9%) 49 (6.1%) 10 (5.1%) 0.59
Beijing strain infection 545 (54.9%) 433 (54.3%) 112 (57.4%) 0.43
Radiographic presentations
Cavity formation 186 (18.8%) 164 (20.6%) 22 (11.3%) 0.003
Lobar/segmental consolidation 807 (81.4%) 637 (79.9%) 170 (87.2%) 0.020
Bilateral involvement 413 (41.6%) 316 (39.6%) 97 (49.7%) 0.010
Respiratory symptoms
Chronic cough 581 (58.6%) 498 (62.5%) 83 (42.6%) ,0.001
Hemoptysis 167 (16.8%) 132 (16.6%) 35 (17.9%) 0.64
Dyspnea 238 (24.0%) 179 (22.5%) 59 (30.3%) 0.022
Constitutional symptoms
Body weight loss 213 (21.5%) 180 (22.6%) 33 (16.9%) 0.08
Fever 301 (30.3%) 218 (27.4%) 83 (42.6%) ,0.001
Malaise 147 (14.8%) 106 (13.3%) 41 (21.0%) 0.006
Anorexia 179 (18.0%) 129 (16.2%) 50 (25.6%) 0.002
aThe data are presented as n (%) unless otherwise stated.
bHIV testing was not routinely done in each patient. The estimated HIV testing rate ranged around 15–20%.
TB, tuberculosis; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; MDR, multi-drug resistance; RR, risk ratio; CI, confidence interval.
doi:10.1371/journal.pone.0023715.t001
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have also been reported to be significant predictors of mortality
[18–21]. In the present study, we found that older age and the
underlying co-morbidities of malignancy and renal insufficiency
were independent demographic characteristics associated with
mortality, whereas drug susceptibility profiles and genotypes of
MTB isolates were not. Drug resistance, especially multidrug
resistance tuberculosis (MDRTB), is widely reported to be
associated with mortality [3,9,21]. However, the associations
between drug resistance and mortality were insignificant in our
report. In Taiwan, MDRTB patients are encouraged to be
transferred to referral TB centers and routinely requested to join a
Direct Observation Therapy/Short Course (DOTS) program.
The treatment regimen is adjusted according to the complete
second line anti-TB drugs susceptibility profiles and is under the
stringent supervision of CDC. All of these measures help to
improve the treatment outcome of MDRTB patients. Our results
indicated that the major determinants for mortality among PTB
patients in Taiwan, a TB endemic area with high medical
accessibility and abundant medical resources, were those factors
related to the underlying conditions of the patients, and not
bacterial factors.
The mortality rates were comparable between PTB patients with
and without HIV-infections in the present study. Taiwan is not a
HIV endemic area and HIV testing is not routinely performed in
general tuberculosis patients. The estimated HIV prevalence rate of
adults in Taiwan was 0.16% in 2008. By comparison, the estimated
HIV prevalence rate was 0.64% in overall newly diagnosed TB
patients and 1.8% in newly diagnosed TB patients with available
HIV testing results [22]. The HIV prevalence rate is likely to be
underestimated as the HIV test is not routinely done for our
patients. The insignificant correlation between HIV infection and
mortality deserves further verification in future studies.
All of the patients we enrolled were culture-proved cases and,
therefore, the genotyping data were available for these patients.
The Beijing genotype is distributed worldwide and is the
predominant MTB strain in Eastern Europe and Southeast Asia
[23,24]. Although previous studies reported higher treatment
failures and relapse rates for patients infected with the Beijing
strain [25,26], the mortality rates were comparable between
patients infected with Beijing and non-Beijing strains in the
present study. Based on these results, the impact of the Beijing
strain on mortality is probably limited in Taiwan. However, the
clinical characteristics, such as drug resistance, associated with the
Beijing strain vary between geographic areas and its role in
treatment outcomes may also be different [23]. Further studies are
required to clarify the impact of the Beijing strain on mortality.
The association between clinical presentations and mortality
remains an issue of controversy. Kourbatova et al. reported
bilateral lung involvement, cavitary lesions on radiograms, and
symptoms lasting . 4 weeks as independent risk factors of
mortality for tuberculosis patients [9]. Hoa et al. also found that
tuberculosis patients with prolonged coughs had an increased risk
of death [10]. However, Venkatarama et al. reported that only
symptomatic dyspnea was independently associated with mortality
for hospitalized tuberculosis patients [8]. Low at al. identified the
absence of cough and cavitary lesions on radiograms as significant
predictors of mortality by multivariate analysis [3].
In our analysis, the presence of fever, anorexia, and the absence
of chronic cough of . 3 weeks were clinical presentations that
were independently associated with mortality. The associations of
radiological features for predicting mortality were limited. More
importantly, we found that the absence of respiratory symptoms,
including chronic cough and dyspnea, was the sole independent
predictor for early mortality within 30 days. The differences in
patient settings, demographic characteristics, and HIV-infection
status may have contributed to the inconsistent findings between
our results and those of previous reports.
Our findings also provide important information for physi-
cians in clinical practice. The presence of constitutional
Table 2. Cox proportional hazards models for overall mortality prediction by demographic characteristics and clinical
presentations.
Unadjusted HR (95% CI)
a Adjusted HR (95% CI)
b
HR (95% CI) p value HR (95% CI) p value
Age 1.06 (1.05–1.07) ,0.001 1.05 (1.04–1.06) ,0.001
Male gender 1.78 (1.19–2.66) 0.005
Malignancy
c 3.59 (2.65–4.87) ,0.001 2.85 (2.08–3.91) ,0.001
Renal insufficiency 3.33 (2.16–5.16) ,0.001 2.27 (1.43–3.59) ,0.001
Post gastrectomy 3.03 (1.76–5.23) ,0.001
Cavitary lesion 0.47 (0.30–0.73) 0.001
Lobar/segmental consolidation 1.77 (1.16–2.71) 0.008
Bilateral involvement 1.44 (1.08–1.90) 0.012
Chronic cough 0.46 (0.34–0.61) ,0.001 0.54 (0.40–0.72) ,0.001
Dyspnea 1.40 (1.03–1.90) 0.031
Fever 1.82 (1.37–2.42) ,0.001 1.72 (1.29–2.30) ,0.001
Malaise 1.54 (1.09–2.18) 0.014
Anorexia 1.60 (1.16–2.21) 0.004 1.49 (1.07–2.07) 0.018
aUnadjusted hazard ratios and 95% confidence intervals for variables that might predict overall mortality (p,0.1).
bResults of stepwise selection for a fitted cox regression model (Goodness-of-fit, Chi square= 214.226, p,0.001). Variables were included in the final model for a p,0.05
and were excluded if p,0.1.
cThe hazard of dying for patients with malignancy or dyspnea attenuated after 6 months and averaged hazard ratios were reported.
HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0023715.t002
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disease severity and associated with increased risk of death.
Meanwhile, respiratory symptoms/signs are important clues
that can remind clinical physicians of the possibility of
pulmonary diseases. The absence of typical respiratory symp-
toms may lessen clinical suspicion and result in delayed
diagnosis of pulmonary tuberculosis. A delayed diagnosis can
lead to increased risks of mortality [27]. However, information
regarding the durations of presenting symptoms/signs was not
collected in the study design. Therefore, the association between
delayed diagnosis and mortality cannot be readily analyzed, and
this made it difficult for us to clarify the interaction between
presenting symptoms/signs and mortality. However, delays in
diagnosis remain the most probable cause for a worse outcome
in patients without respiratory symptoms.
Possible predictors of early mortality as compared with late
mortality among PTB patients have rarely been analyzed before.
Interestingly, we found that only the absence of respiratory
symptoms, but neither age nor co-morbidities, was an independent
predictor of mortality within 30 days. The findings again
emphasize the importance of early diagnosis and early treatment
in the improving outcome of PTB patients. The proportions of
previous TB history were comparable between patient with early
and late mortality in the present study. However, the impact of TB
reaction remains an issue that deserves discussion as critical
patients probably are more likely to have TB reactivation and this
leads to early mortality. This study was carried out in a TB
endemic area and unrecognized previous TB infection is highly
possible with uncertain incidence. The proportion of previous TB
infection is obviously underestimated. However, a history of
previous TB infection does not necessarily indicate the presence of
reactivation, as reinfection could be a major cause of recurrent TB
after previous cure [28]. Without genotyping profiles of previous
infection, it is difficult to differentiate TB reactivation from TB
reinfection in these patients. Further studies are needed to
elucidate this issue.
Figure 3. Kaplan-Meier survival curves of pulmonary tuberculosis patients stratified by the presence or absence of clinical
symptoms/signs. (A) Chronic cough . three weeks. (B) Dyspnea. (C) Fever. (D) Anorexia. Significances were tested using the log-rank test.
doi:10.1371/journal.pone.0023715.g003
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present study. Unfortunately, all of these were un-modifiable
factors. What actions can we take when managing these high risk
patients? Irrespective of the cause of mortality, treating the
underlying comorbidities of patients as best as possible is definitely
important. It would be helpful to encourage the patients to join a
DOTS program to enhance compliance of anti-TB treatment.
However, the crucial step probably lies in early anti-TB treatment;
and early treatment mostly depends on early diagnosis. Maintain-
ing a high degree of clinical suspicion in order to diagnosis PTB
early is of pivotal importance to improve the treatment outcome of
PTB patient.
Our study had several limitations. Five of the six participating
hospitals were regional referral medical centers. More patients with
more co-morbidities and higher disease severities may have been
included in the present study and, as a result, the overall mortality
rate may have been overestimated. However, this also shows that
our findings can be reliably applied to elderly PTB patients with
multiple co-morbidities. Information regarding the durations of
presentingsymptomspriortoPTBdiagnosiswasnotcollectedinthe
study design. This limitation made it more difficult to interpret the
association between symptoms/signs and mortality. We did not
divide deaths as being due to either TB or other non-TB causes in
the study design because it is not always easy to identify the impact
of tuberculosis on mortality. All-cause mortality is more objective
and more applicable to clinical practice. As the study area not an
HIV endemic area, HIV testing was not routinely conducted in the
present study. This also limits the ability of our findings to be
applied in non-HIV-endemic areas.
In conclusion, our study found that nearly one-third of the
mortality cases among PTB patients occurred within 30 days of
initiating anti-TB treatment. Irrespective of the cause of mortality,
older age and the underlying co-morbidities of malignancy and
renal insufficiency were demographic characteristics that associ-
ated with death. Regarding clinical presentations, the presence of
fever, anorexia, and the absence of chronic cough were
independent predictors of death. As compared with late mortality,
the absence of respiratory symptoms, including chronic cough and
dyspnea, were significant factors associated with early mortality
within 30 days. In contrast, the associations of radiological features
with early and overall mortalities were limited.
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Table 3. Poisson regression analysis for early mortality (within 30 days) prediction by demographic characteristics and clinical
presentations.
a,b
All mortality
patients, n=195 Mortality status Unadjusted RR (95% CI)
c Adjusted RR (95% CI)
d
Early mortality,
n=62
Late mortality,
n=133 RR (95% CI) P value RR (95% CI) P value
Mean Age (SD) 76.2 (12.6) 77.2 (15.3) 75.7 (11.2) 1.01 (0.99–1.03) 0.53
Initial sputum smear positive 91 (46.7%) 22 (35.5%) 69 (51.9%) 0.63 (0.41–0.97) 0.033
Previous TB history 18 (9.2%) 3 (4.8%) 15 (11.3%) 0.50 (0.17–1.43) 0.16
Malignancy 61 (31.3%) 17 (27.4%) 44 (33.1%) 0.83 (0.52–1.33) 0.43
Renal insufficiency 23 (11.8%) 11 (17.7%) 12 (9%) 1.61 (0.99–2.62) 0.08
Post gastrectomy 14 (7.2%) 4 (6.5%) 10 (7.5%) 0.89 (0.38–2.10) 0.79
Isoniazid resistance 23 (11.8%) 4 (6.5%) 19 (14.3%) 0.52 (0.21–1.29) 0.11
Rifampicin resistance 11 (5.6%) 1 (1.6%) 10 (7.5%) 0.27 (0.04–1.80) 0.10
MDR 10 (5.1%) 1 (1.6%) 9 (6.8%) 0.30 (0.05–1.97) 0.13
Beijing strain infection 112 (57.4%) 35 (56.5%) 77 (57.9%) 0.96 (0.63–1.45) 0.85
Cavity formation 22 (11.3%) 7 (11.3%) 15 (11.3%) 1.00 (0.52–1.92) 1.00
Lobar/segmental consolidation 170 (87.2%) 54 (87.1%) 116 (87.2%) 0.99 (0.54–1.83) 0.98
Chronic cough 83 (42.6%) 17 (27.4%) 66 (49.6%) 0.51 (0.32–0.82) 0.003 0.56 (0.33–0.98) 0.041
Hemoptysis 35 (17.9%) 16 (25.8%) 19 (14.3%) 1.59 (1.03–2.46) 0.05
Dyspnea 59 (30.3%) 11 (17.7%) 48 (36.1%) 0.50 (0.28–0.88) 0.009 0.51 (0.27–0.98) 0.043
Fever 83 (42.6%) 27 (43.5%) 56 (42.1%) 1.04 (0.69–1.57) 0.85
Malaise 41 (21.0%) 16 (25.8%) 25 (18.8%) 1.31 (0.83–2.05) 0.26
Anorexia 50 (25.6%) 11 (17.7%) 39 (29.3%) 0.63 (0.35–1.10) 0.09
aThe data are presented as n (%) unless otherwise stated.
bOnly mortality cases are included for analysis.
cUnadjusted risk ratios and 95% confidence intervals for clinically relevant variables.
dResults of stepwise selection for a fitted Poisson Regression model (Goodness-of-fit, Chi square=9.55, p=0.008). Variables were included in the final model for p,0.05
and were excluded if p,0.1.
TB, tuberculosis; MDR, multi-drug resistance; RR, risk ratio; CI, confidence interval.
doi:10.1371/journal.pone.0023715.t003
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